{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:13:21Z","timestamp":1790162001349,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-2945-8","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T12:47:29Z","timestamp":1516020449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy"],"prefix":"10.1186","volume":"18","author":[{"given":"Francesca","family":"Carozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donella","family":"Puliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ocello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale Silvio","family":"Anastasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espedito Antonio","family":"Moliterni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Perinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Serradell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Confortini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mantellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Dominiak-Felden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"2945_CR1","first-page":"S462","volume":"12","author":"H Trottier","year":"2006","unstructured":"Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care. 2006;12:S462\u201372.","journal-title":"Am J Manag Care"},{"key":"2945_CR2","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","volume":"32","author":"JG Baseman","year":"2005","unstructured":"Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32:S16\u201324.","journal-title":"J Clin Virol"},{"issue":"14","key":"2945_CR3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/jnci\/dji187","volume":"97","author":"MJ Khan","year":"2005","unstructured":"Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2945_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048\u201356.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2945_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1750-9378-7-38","volume":"7","author":"B Serrano","year":"2012","unstructured":"Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.","journal-title":"Infect Agent Cancer"},{"key":"2945_CR6","unstructured":"ICO Information Centre on HPV and Cancer. \n                    www.hpvcentre.net\n                    \n                   (data updated in June 2016). Available: \n                    http:\/\/www.hpvcentre.net\/statistics\/reports\/ITA_FS.pdf\n                    \n                   and \n                    http:\/\/www.hpvcentre.net\/statistics\/reports\/ITA.pdf\n                    \n                  ."},{"issue":"19","key":"2945_CR7","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Females United to Unilaterally Reduce Endo\/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928\u201343.","journal-title":"N Engl J Med"},{"issue":"9686","key":"2945_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","volume":"374","author":"J Paavonen","year":"2009","unstructured":"Paavonen J, Naud P, Salmer\u00f3n J, Wheeler CM, Chow SN, Apter D, et al. HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301\u201314.","journal-title":"Lancet"},{"issue":"Suppl 5","key":"2945_CR9","doi-asserted-by":"publisher","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","volume":"30","author":"LE Markowitz","year":"2012","unstructured":"Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction\u2013the first five years. Vaccine. 2012;30(Suppl 5):F139\u201348.","journal-title":"Vaccine"},{"issue":"2","key":"2945_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/hv.7.2.13690","volume":"7","author":"B Romanowski","year":"2011","unstructured":"Romanowski B. Long term protection against cervical infection with the humanpapillomavirus: review of currently available vaccines. Hum Vaccin. 2011;7(2):161\u20139.","journal-title":"Hum Vaccin"},{"key":"2945_CR11","unstructured":"Italian National Institute of Statistics. Demography in figures. Available at: \n                    www.demo.istat.it\n                    \n                  . Accessed 11 August, 2017."},{"key":"2945_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2334-13-74","volume":"13","author":"C Giambi","year":"2013","unstructured":"Giambi C, Donati S, Carozzi F, Salmaso S, Declich S, Atti ML, et al. A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18\u201326 years. BMC Infect Dis. 2013;13:74.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"2945_CR13","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1158\/1055-9965.EPI-08-0180","volume":"17","author":"P Ammatuna","year":"2008","unstructured":"Ammatuna P, Giovannelli L, Matranga D, Ciriminna S, Perino A. Prevalence of genital human papilloma virus infection and genotypes among young women in Sicily, South Italy. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2002\u20136.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2945_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1471-2334-10-214","volume":"10","author":"P Giorgi Rossi","year":"2010","unstructured":"Giorgi Rossi P, Bisanzi S, Paganini I, Di Iasi A, Angeloni C, Scalisi A, et al. HPV Prevalence Italian Working Group. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect Dis. 2010;10:214.","journal-title":"BMC Infect Dis"},{"issue":"26 Suppl 10","key":"2945_CR15","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","volume":"19","author":"FX Bosch","year":"2008","unstructured":"Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;19(26 Suppl 10):K1\u201316.","journal-title":"Vaccine"},{"issue":"2","key":"2945_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canep.2009.12.010","volume":"34","author":"G Ripabelli","year":"2010","unstructured":"Ripabelli G, Grasso GM, Del Riccio I, Tamburro M, Sammarco ML. Prevalence and genotype identification of human papillomavirus in women undergoing voluntary cervical cancer screening in Molise, central Italy. Cancer Epidemiol. 2010;34(2):162\u20137.","journal-title":"Cancer Epidemiol"},{"issue":"Suppl 1","key":"2945_CR17","doi-asserted-by":"publisher","first-page":"A11","DOI":"10.1016\/j.vaccine.2008.10.095","volume":"27","author":"G Masia","year":"2009","unstructured":"Masia G, Mazzoleni AP, Contu G, Laconi S, Minerba L, Montixi S, et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Sardinia (Italy). Vaccine. 2009;27(Suppl 1):A11\u20136.","journal-title":"Vaccine"},{"issue":"3","key":"2945_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/jmv.21347","volume":"81","author":"A Agarossi","year":"2009","unstructured":"Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol. 2009;81(3):529\u201335.","journal-title":"J Med Virol"},{"issue":"11","key":"2945_CR19","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/infdis\/jis590","volume":"206","author":"SN Tabrizi","year":"2012","unstructured":"Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206(11):1645\u201351.","journal-title":"J Infect Dis"},{"issue":"3","key":"2945_CR20","doi-asserted-by":"publisher","first-page":"e20151968","DOI":"10.1542\/peds.2015-1968","volume":"137","author":"LE Markowitz","year":"2016","unstructured":"Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968.","journal-title":"Pediatrics"},{"issue":"11","key":"2945_CR21","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/ijc.25940","volume":"129","author":"RM Haupt","year":"2011","unstructured":"Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, et al. FUTURE I and II Investigators. Impact of an HPV6\/11\/16\/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16\/18 infection. Int J Cancer. 2011;129(11):2632\u201342.","journal-title":"Int J Cancer"},{"issue":"5","key":"2945_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"N Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325\u201339.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2945_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/bjc.2011.185","volume":"105","author":"X Castellsagu\u00e9","year":"2011","unstructured":"Castellsagu\u00e9 X, Mu\u00f1oz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age. Br J Cancer. 2011;105(1):28\u201337.","journal-title":"Br J Cancer"},{"issue":"7","key":"2945_CR24","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1086\/597309","volume":"199","author":"CM Wheeler","year":"2009","unstructured":"Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years. J Infect Dis. 2009;199(7):936\u201344.","journal-title":"J Infect Dis"},{"issue":"1","key":"2945_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","volume":"13","author":"CM Wheeler","year":"2012","unstructured":"Wheeler CM, Castellsagu\u00e9 X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100\u201310.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2945_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","volume":"12","author":"T Malag\u00f3n","year":"2012","unstructured":"Malag\u00f3n T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2945_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/aje\/kwt018","volume":"178","author":"JE Tota","year":"2013","unstructured":"Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type-replacement postvaccination. Am J Epidemiol. 2013;178(4):625\u201334.","journal-title":"Am J Epidemiol"},{"issue":"10","key":"2945_CR28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","volume":"14","author":"SN Tabrizi","year":"2014","unstructured":"Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination program in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014t;14(10):958\u201366.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2945_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","volume":"15","author":"M Drolet","year":"2015","unstructured":"Drolet M, B\u00e9nard \u00c9, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programs: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565\u201380.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"2945_CR30","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1038\/bjc.2014.198","volume":"110","author":"K Kavanagh","year":"2014","unstructured":"Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types. Br J Cancer. 2014;110(11):2804\u201311.","journal-title":"Br J Cancer"},{"issue":"10","key":"2945_CR31","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3201\/eid2210.160675","volume":"22","author":"D Mesher","year":"2016","unstructured":"Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JML, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis. 2016;22(10):1732\u201340.","journal-title":"Emerg Infect Dis"},{"issue":"23","key":"2945_CR32","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1016\/j.vaccine.2012.03.065","volume":"30","author":"YH Choi","year":"2012","unstructured":"Choi YH, Chapman R, Gay N, Jit M. Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model. Vaccine. 2012;30(23):3383\u20138.","journal-title":"Vaccine"},{"issue":"11","key":"2945_CR33","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1128\/JCM.00918-10","volume":"48","author":"C Eklund","year":"2010","unstructured":"Eklund C, Zhou T. Dillner J; WHO Human Papillomavirus Laboratory Network. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol. 2010;48(11):4147\u201355.","journal-title":"J Clin Microbiol"},{"issue":"7","key":"2945_CR34","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1128\/JCM.00840-12","volume":"50","author":"C Eklund","year":"2012","unstructured":"Eklund C, Forslund O, Wallin KL, Zhou T, Dillner J. WHO Human Papillomavirus Laboratory Network. The 2010 global proficiency study of human papilloma virus genotyping in vaccinology. J Clin Microbiol. 2012;50(7):2289\u201398.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"2945_CR35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323.","journal-title":"N Engl J Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-2945-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:11:25Z","timestamp":1547511085000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-2945-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2945"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-2945-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]},"assertion":[{"value":"22 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the patients gave a proper informed consent to participate in the study. The study was approved by the Matera LHU ethics committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following interests:FC, DP, CO, EB, MC, PM, and MZ report funding provided by Sanofi-Pasteur MSD, the study sponsor, to their employing institution (ISPO), to perform study-related activities.EAM and PSA report funding provided by Sanofi-Pasteur MSD, the study sponsor, to their employing institution, to perform study-related activities.GDF, LS, and EP were employees of Sanofi-Pasteur MSD at the time the study was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"38"}}